Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial

Andrea Massimiliano Tomirotti, PhD, Daniela Bellarosa, Scott R. Solomon, MD, Aziz Nazha, MD, Stephen A Strickland, MD MSCI, Roland P Walter, MDPhD, Farhad Ravandi, MBBS, Krzysztof Brzózka, PhD, Milena Mazan, PhD, Simone Baldini, MD, Massimiliano Salerno, Monica Binaschi, PhD, Dirk Laurent, MD, Andrea Pellacani, PhD MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136936

Published: 2020

Journal Articles

The VITAL Trial: Phase II Trial of V osaroxin and I nfusional Cytarabine for Frontline T reatment of a cute Myeloid L eukemia

Stephen A Strickland, MD MSCI, Nikolai A. Podoltsev, MD PhD, Sanjay R Mohan, MD MSCI, Amer M. Zeidan, MBBS, MHS, Merrida A Childress, PhD, Gregory D Ayers, MS, Michael T Byrne, DO, Steven D. Gore, MD, Robert K. Stuart, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 180.

https://doi.org/10.1182/blood-2019-131520

Published: 2019

Journal Articles

Radius-X: An Expanded Treatment Protocol of Midostaurin in Adults with Newly Diagnosed FLT3 -Mutation-Positive Acute Myeloid Leukemia Eligible for Standard Chemotherapy

Gail J. Roboz, MD, Stephen A. Strickland, MD MSCI, Mark R. Litzow, MD, Andrew Dalovisio, MD, Alexander E. Perl, MD, Gaetano Bonifacio, MD, Kelly Haines, Alysha Barbera, Das Purkayastha, Kendra Sweet, MD

Blood (2017) 130 (Supplement 1): 1338.

https://doi.org/10.1182/blood.V130.Suppl_1.1338.1338

Published: 2017

Journal Articles

Rates of Adverse Events per Patient-Year in a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Bruno C Medeiros, MD, Jeffrey E. Lancet, MD, Jorge E. Cortes, MD, Laura F. Newell, MD, Tara L. Lin, MD, Ellen K Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, MD MSCI, Donna Hogge, Scott R Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, Jonathan E. Kolitz, MD, Gary J. Schiller, Matthew J. Wieduwilt, Robert J. Ryan, Michael Chiarella, Arthur C Louie, Geoffrey L. Uy, MD

Blood (2017) 130 (Supplement 1): 1366.

https://doi.org/10.1182/blood.V130.Suppl_1.1366.1366

Published: 2017

Journal Articles

Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes

Andrew Wei, MBBS, PhD FRACP, FRCPA, Stephen A. Strickland, MD MSCI, Gail J. Roboz, MD, Jing-Zhou Hou, MD PhD, Walter Fiedler, MD, Tara L. Lin, MD, Roland B. Walter, MD PhD, Anoop Enjeti, MD MRCP, FRCPA, MClin Epid, GradCert Bioethics, Brenda Chyla, PhD, Relja Popovic, PhD, Kaffa Fakouhi, Pooja Shah, Martin Dunbar, DRPH, MS, Tu Xu, PhD, Mack Mabry, MD, John Hayslip, MD MSCR

Blood (2017) 130 (Supplement 1): 890.

https://doi.org/10.1182/blood.V130.Suppl_1.890.890

Published: 2017

Journal Articles

Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of Acute Myeloid Leukemia (VITAL) Patients Eligible for Intensive Chemotherapy: A Planned Interim Analysis

Stephen A. Strickland, MD MSCI, Nikolai A. Podoltsev, MD PhD, Sanjay R. Mohan, MD MSCI, Amer M. Zeidan, MD, Gregory D. Ayers, MS, Molly Olson, MS, Steven D. Gore, MD, Robert K. Stuart, MD, Michael R. Savona, MD

Blood (2017) 130 (Supplement 1): 2630.

https://doi.org/10.1182/blood.V130.Suppl_1.2630.2630

Published: 2017

Journal Articles

A Suppressive Microenvironment in Acute Myeloid Leukemia Induces Global Alteration of T and NK Cell Profiles - Evidence for Immune-Editing Effect By Leukemia

Sawa Ito, MD, John Barrett, MD, Bipin N. Savani, MD, Madan Jagasia, MBBS, MS, Eolia Brissot, Samantha Miner, Nancy F. Hensel, Fariba Chinian, M.S., Keyvan Keyvanfar, BS, Minoo Battiwalla, MD MS, Michael R Savona, MD, Sanjay Mohan, MD, Mattias Carlsten, MD PhD, Pawel Muranski, MD, Stephen A. Strickland, MD MSCI

Blood (2014) 124 (21): 1047.

https://doi.org/10.1182/blood.V124.21.1047.1047

Published: 2014

Journal Articles

T Cell Exhaustion and Downregulation of Cytotoxic NK Cells – an Immune Escape Mechanism in Adult Acute Lymphoblastic Leukemia

Eolia Brissot, Sawa Ito, MD, Kit Lu, MD, Carly Cantilena, B. Douglas Smith, Gabrielle Prince, Hossein Sadrzadeh, Amir T Fathi, Stephen A. Strickland, MD MSCI, Nancy F. Hensel, Fariba Chinian, M.S., Keyvan Keyvanfar, BS, Minoo Battiwalla, MDMS, Pawel Muranski, MD, Christopher S. Hourigan, MDPhD, John Barrett, MD

Blood (2014) 124 (21): 3781.

https://doi.org/10.1182/blood.V124.21.3781.3781

Published: 2014

Journal Articles

High Levels Of IL-27 Occur In Newly Diagnosed Acute Myeloid Leukemia (AML) and May Influence Outcome By Suppressing T Cell Function

Nicole Stephens, BS, Sawa Ito, Stephen A. Strickland, MD, MSCI, Bipin N. Savani, MD, Madan Jagasia, MBBS, MS, J. Joseph Melenhorst, PhD, Fang Yin, MD, Nancy F. Hensel, Fariba Chinian, M.S., Xingmin Feng, PhD, Leigh Samsel, MS, Keyvan Keyvanfar, BS, Christopher S. Hourigan, MD, PhD, Minoo Battiwalla, MD, MS, Pawel Muranski, MD, A. John Barrett

Blood (2013) 122 (21): 2567.

https://doi.org/10.1182/blood.V122.21.2567.2567

Published: 2013

Journal Articles

SAR650984, a CD38 Monoclonal Antibody In Patients With Selected CD38+ Hematological Malignancies- Data From a Dose-Escalation Phase I Study

Thomas G Martin, III, MD, Stephen A. Strickland, MD, MSCI, Martha Glenn, MD, Wei Zheng, PhD, Nikki Daskalakis, MD, Joseph R. Mikhael, MD

Blood (2013) 122 (21): 284.

https://doi.org/10.1182/blood.V122.21.284.284

Published: 2013

Journal Articles

Myeloid-Derived Suppressor Phenotype of Leukemic Blasts in Association with Increased Suppressor T Cell Subsets in Acute Myelogenous Leukemia– Evidence for Immunoediting.

Sawa Ito, MD, Stephen A. Strickland, MD, MSCI, Bipin N. Savani, MD, J. Joseph Melenhorst, Ph.D., Fang Yin, MD, Pawel Muranski, MD, Nancy F. Hensel, BS, Fariba Chinian, M.S., Keyvan Keyvanfar, BS, Christopher S. Hourigan, MD, PhD, Minoo Battiwalla, MD, MS, A. John Barrett, MD

Blood (2012) 120 (21): 2528.

https://doi.org/10.1182/blood.V120.21.2528.2528

Published: 2012

Journal Articles

Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)

Joshua F. Zeidner, MD, Jonathan M. Gerber, MD, Amanda Blackford, Mark Litzow, MD, Matthew C. Foster, MD, Lawrence E. Morris, Jr., MD, Ivana Gojo, MD, Jeffrey E. Lancet, MD, Prithviraj Bose, MD, Raoul Tibes, MD, Stephen A. Strickland, MD, MSCI, Jacqueline M Greer, RN, Michelle Drye, Kevin Meads, Austin Doyle, MD, Richard F Little, MD, MPH, John J Wright, MD, PhD, Judith E. Karp, MD

Blood (2012) 120 (21): 47.

https://doi.org/10.1182/blood.V120.21.47.47

Published: 2012

Journal Articles

Evidence-Based, Patient-Specific Guidelines Provide Efficient and Cost-Effective Molecular and Cytogenetic Testing in Hematologic Malignancy

Adam C. Seegmiller, MD, PhD, Annette S. Kim, MD, PhD, Claudio A. Mosse, MD, PhD, Mia A. Levy, MD, PhD, Mary Ann Thompson, MD, PhD, Megan K. Kressin, MD, Madan H. Jagasia, MD, Stephen A. Strickland, MD, MSCI, Nishitha M. Reddy, MD, Kristy J. Sinkfield, Samuel A. Santoro, MD, PhD, Mary M. Zutter, MD

Blood (2011) 118 (21): 2073.

https://doi.org/10.1182/blood.V118.21.2073.2073

Published: 2011

Journal Articles

Monosomal Karyotype (MK) In Older Patients with Acute Myeloid Leukemia (AML) on Eastern Cooperative Oncology Group (ECOG) Therapeutic Trials: Poor Prognostic Impact of MK, but Not of Monosomy 7

Stephen A Strickland, MD, MSCI, Zhuoxin Sun, PhD, Rhett P Ketterling, MD, Athena M Cherry, PhD, Larry D Cripe, MD, Gordon Dewald, PhD, Rodney R Higgins, PhD, MS, Hillard M Lazarus, MD, Mark R Litzow, MD, Selina M Luger, MD, Elisabeth Paietta, PhD, Jacob M Rowe, MD, Hajime Uno, PhD, Gail H Vance, MD, Martin S Tallman, MD

Blood (2010) 116 (21): 579.

https://doi.org/10.1182/blood.V116.21.579.579

Published: 2010

NARROW

SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial

The VITAL Trial: Phase II Trial of V osaroxin and I nfusional Cytarabine for Frontline T reatment of a cute Myeloid L eukemia

Radius-X: An Expanded Treatment Protocol of Midostaurin in Adults with Newly Diagnosed FLT3 -Mutation-Positive Acute Myeloid Leukemia Eligible for Standard Chemotherapy

Rates of Adverse Events per Patient-Year in a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes

Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of Acute Myeloid Leukemia (VITAL) Patients Eligible for Intensive Chemotherapy: A Planned Interim Analysis

A Suppressive Microenvironment in Acute Myeloid Leukemia Induces Global Alteration of T and NK Cell Profiles - Evidence for Immune-Editing Effect By Leukemia

T Cell Exhaustion and Downregulation of Cytotoxic NK Cells – an Immune Escape Mechanism in Adult Acute Lymphoblastic Leukemia

High Levels Of IL-27 Occur In Newly Diagnosed Acute Myeloid Leukemia (AML) and May Influence Outcome By Suppressing T Cell Function

SAR650984, a CD38 Monoclonal Antibody In Patients With Selected CD38+ Hematological Malignancies- Data From a Dose-Escalation Phase I Study

Myeloid-Derived Suppressor Phenotype of Leukemic Blasts in Association with Increased Suppressor T Cell Subsets in Acute Myelogenous Leukemia– Evidence for Immunoediting.

Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)

Evidence-Based, Patient-Specific Guidelines Provide Efficient and Cost-Effective Molecular and Cytogenetic Testing in Hematologic Malignancy

Monosomal Karyotype (MK) In Older Patients with Acute Myeloid Leukemia (AML) on Eastern Cooperative Oncology Group (ECOG) Therapeutic Trials: Poor Prognostic Impact of MK, but Not of Monosomy 7

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only